Pharma, Biopharma & Advanced Modalities

Independent Technical Stewardship for India’s Life Sciences Ecosystem

Pharma, Biopharma & Advanced Modalities

India has emerged as a preferred destination for cost-effective, high-quality pharma and biopharma development and manufacturing. With world-class capabilities across small molecules, biologics, and emerging modalities, Indian partners can deliver innovation at speed. However, success depends not just on access to capability-but on choosing the right partners and actively managing technical, regulatory, and execution risk.

Aventiq Bio bridges global innovators with India’s top-tier ecosystem through independent technical governance. We provide partner scouting and qualification, due diligence, tech-transfer oversight, regulatory and quality advisory, and program-level governance across the lifecycle. Our model ensures your programs remain audit-ready, globally compliant, and scientifically defensible-while capturing 40–60% cost advantages without compromise.

Our Specialized Expertise by Modality

01.

Small Molecules (NCEs & Generics)

Bridging the gap between lab-scale discovery and GMP reality. We provide the independent vetting and on-ground governance required to navigate India’s ecosystem with absolute certainty. We offer the full small molecule lifecycle-from target validation.

02.

HPAPI (Highly Potent APIs)

Aventiq Bio provides the technical governance required to tap into India’s elite HPAPI capacity with absolute safety, regulatory certainty, and 40–60% cost advantages. We don't just find you a manufacturer; we build a firewall around your potent IP and your global reputation.

03.

Biologics (Biosimilars & mAbs)

From cell line development to commercial scale-up - Aventiq Bio provides independent technical governance for mAbs, recombinant proteins, and biosimilars in India’s leading biopharma hubs

04.

ADCs (Antibody-Drug Conjugates)

ADCs are the most complex modalities in modern medicine. Managing the fragile intersection of potent Cytotoxic Payload synthesis and delicate protein conjugation requires more than a vendor - it requires Integrated Governance.

05.

Cell & Gene Therapy (CGT)

06.

Vaccines

Vaccine programs demand flawless execution at unprecedented scale, yet outsourcing to high-volume facilities introduces risks: lot variability, cold chain breaks, and aseptic breaches that can compromise immunogenicity or trigger recalls.

07.

Precision Medicine & Genomics

Aventiq Bio serves as your Independent Technical Proxy in India. We provide high-level governance for NGS platforms, biomarkers, and Companion Diagnostics (CDx), ensuring that genomics-driven programs are built on audit-ready data and defensible partner intelligence.

Expert consulting for partner selection, tech transfer oversight, regulatory compliance, and end-to-end project governance across complex modalities.

Partner Scouting & Due Diligence :

Independent evaluation and qualification of 500+ CRO/CDMO and manufacturing facilities across India
Tech Transfer & Process Oversight :

Governance of scale-up, validation, and inter-site hand-offs to ensure reproducibility and compliance
Regulatory & Quality Advisory

Strategic support for FDA/EMA-aligned filings, audit readiness, and ALCOA+ data integrity.
Program Governance & Risk Management

Centralized oversight of timelines, costs, vendors, and risk across the development lifecycle.

How Aventiq Intervenes

Independent scouting and qualification of CDMOs and CROs for ADCs, CGT, biologics, and complex small molecules.

On-ground technical, quality, and compliance audits aligned with FDA and EMA expectations.

Governance of tech transfer, process scale-up, and CMC readiness, including ALCOA+ data integrity enforcement.

Continuous oversight and program rescue when execution or inspection readiness is at risk.

Outcome:
Confident, well-documented partner selection; globally defensible data packages; predictable execution; and materially reduced FDA/EMA inspection risk.

Pharma, Biopharma & Advanced Modalities